



Implementing BARDA's Pandemic Preparedness and Response Capability

Gary Disbrow, Ph.D

Director, Biomedical Advanced Research and Development Authority
Deputy Assistant Secretary for Preparedness and Response
Department of Health and Human Services

The BARDA Model

BARDA develops and makes available medical countermeasures (MCMs) by forming unique public-private partnerships to drive innovation off the bench to the patient to save lives.



Flexible, nimble authorities


Multi-year funding

Cutting edge expertise


Facilitate partnerships

Promote innovation

BARDA's Medical Countermeasure Development Pipeline



65 FDA Approvals, Licensures, and Clearances





COVID-19 Response

146

COVID-19 Partnerships

4724

Market Research Submissions

789

CoronaWatch Meetings

3

FDA Approvals, Licensures, and Clearances

29

Diagnostic Test EUAs

286M

Diagnostic Test Kits Shipped

Emergency Use Authorizations Supported by the USG

4

Vaccines

8

Therapeutics

105

Products Supported

\$80

billion

Awarded

\$47.5B

vaccines

\$31.4B

therapeutics

\$.81B

diagnostics

COVID-19 Vaccine Doses

918M

Delivered

653M

Administered

As of 12/01/2022

BARDA's Role in Future Pandemic Preparedness



American Pandemic Preparedness: Transforming Our Capabilities

September 2021

I. Transforming our Medical Defenses

Goal: Have the ability to rapidly make effective vaccines against any virus family.

Goal: Have a range of therapeutics suitable for any virus family, available before a pandemic or readily created during a pandemic.

Goal: Have simple, inexpensive, high-performance diagnostic tests available at large scale within weeks after the recognition of an emerging pandemic threat.

<https://www.whitehouse.gov/briefing-room/statements-releases/2021/09/03/fact-sheet-biden-administration-to-transform-capabilities-for-pandemic-preparedness/>

The Challenge and Opportunity

1.2 Vaccine R&D


“Enable design, testing, and review of a safe and effective vaccine against any human virus within 100 days after the recognition of a potential emerging pandemic threat”

1.2 Vaccine Production

“Enable production of enough vaccine for the entire United States population within 130 days and for the global population within 200 days after its recognition as a potential emerging pandemic threat”


3.0 Diagnostics

“Simple, inexpensive, accurate tests for any virus available within weeks”



A Bold Vision


What is BARDA's model to implement rapid partnering and manufacturing?



Objective 2.1

“Enhance BARDA's response posture by leveraging a diverse MCM portfolio of proven technologies”

Benefits of Regulatory Approval to Response and Access





medicalcountermeasures.gov

*Portal to BARDA: **Register to request a TechWatch meeting!***



[sam.gov/](https://sam.gov)

*Official announcements
and info for all government
contract solicitations*



aspr.hhs.gov/MCM/

*Program description,
information, news,
announcements*



drive.hhs.gov

*Learn about DRIVE,
including our Accelerator
Network and EZ BAA*



www.usajobs.gov

Join the team!



@BARDA



Biomedical Advanced Research and Development Authority



@BARDAGOV